Michael H Parker, PhD - Publications

University of California, Los Angeles, Los Angeles, CA 

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Guan H, Nuth M, Lee V, Lin C, Mitchell CH, Lu W, Scott RW, Parker MH, Kulp JL, Reitz AB, Ricciardi RP. Herpes simplex Virus-1 infection in human primary corneal epithelial cells is blocked by a stapled peptide that targets processive DNA synthesis. The Ocular Surface. PMID 33161128 DOI: 10.1016/j.jtos.2020.11.001  1
2018 Nuth M, Guan H, Xiao Y, Kulp JL, Parker MH, Strobel ED, Isaacs SN, Scott RW, Reitz AB, Ricciardi RP. Mutation and structure guided discovery of an antiviral small molecule that mimics an essential C-terminal tripeptide of the vaccinia D4 processivity factor. Antiviral Research. PMID 30578797 DOI: 10.1016/j.antiviral.2018.12.011  1
2018 Lu T, Schubert C, Cummings MD, Bignan G, Connolly PJ, Smans K, Ludovici D, Parker MH, Meyer C, Rocaboy C, Alexander R, Grasberger B, De Breucker S, Esser N, Fraiponts E, et al. Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy. Bioorganic & Medicinal Chemistry Letters. PMID 29779975 DOI: 10.1016/j.bmcl.2018.05.014  0.01
2014 Bignan G, Alexander R, Bischoff J, Connolly P, Cummings M, de Breucker S, Esser N, Fraiponts E, Gilissen R, Grasberger B, Janssens B, Lu T, Ludovici D, Meerpoel L, Meyer C, ... Parker M, et al. 430 Design and structure–activity relationships of highly potent and bioavailable imidazolinone FASN KR domain inhibitors European Journal of Cancer. 50: 141-142. DOI: 10.1016/S0959-8049(14)70556-8  0.01
2013 McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White HS, Klein BD, Wilcox KS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Reitz AB, et al. Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112). Journal of Medicinal Chemistry. 56: 9019-30. PMID 24205976 DOI: 10.1021/jm400894u  1
2011 Tounge BA, Parker MH. Designing a diverse high-quality library for crystallography-based FBDD screening. Methods in Enzymology. 493: 3-20. PMID 21371585 DOI: 10.1016/B978-0-12-381274-2.00001-7  0.01
2010 Huang Y, Strobel ED, Ho CY, Reynolds CH, Conway KA, Piesvaux JA, Brenneman DE, Yohrling GJ, Moore Arnold H, Rosenthal D, Alexander RS, Tounge BA, Mercken M, Vandermeeren M, Parker MH, et al. Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads. Bioorganic & Medicinal Chemistry Letters. 20: 3158-60. PMID 20399652 DOI: 10.1016/j.bmcl.2010.03.097  1
2010 Posner GH, Parker MH, Northrop J, Elias JS, Ploypradith P, Xie S, Shapiro TA. ChemInform Abstract: Orally Active, Hydrolytically Stable, Semisynthetic, Antimalarial Trioxanes in the Artemisinin Family. Cheminform. 30: no-no. DOI: 10.1002/chin.199923194  0.01
2010 WOO SH, PARKER MH, PLOYPRADITH P, NORTHROP J, POSNER GH. ChemInform Abstract: Direct Conversion of Pyranose Anomeric OH→F→R in the Artemisinin Family of Antimalarial Trioxanes. Cheminform. 29: no-no. DOI: 10.1002/CHIN.199822137  0.01
2009 Reitz AB, Smith GR, Parker MH. The role of sulfamide derivatives in medicinal chemistry: a patent review (2006-2008). Expert Opinion On Therapeutic Patents. 19: 1449-53. PMID 19650745 DOI: 10.1517/13543770903185920  1
2009 Parker MH, Smith-Swintosky VL, McComsey DF, Huang Y, Brenneman D, Klein B, Malatynska E, White HS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Iannucci R, et al. Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies. Journal of Medicinal Chemistry. 52: 7528-36. PMID 19388676 DOI: 10.1021/jm801432r  1
2008 Falcone BV, Creighton CJ, Parker MH, Reitz AB. Synthesis of bis-phenylalanine, a novel eight-membered cyclic dipeptide Synthetic Communications. 38: 411-418. DOI: 10.1080/00397910701771090  1
2008 Falcone BV, Creighton CJ, Parker MH, Reitz AB. ChemInform Abstract: Synthesis of Bis-phenylalanine, a Novel Eight-Membered Cyclic Dipeptide. Cheminform. 39. DOI: 10.1002/CHIN.200827188  0.01
2007 Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR. The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Medicinal Chemistry (Shariqah (United Arab Emirates)). 3: 543-5. PMID 18045203  1
2007 Baxter EW, Conway KA, Kennis L, Bischoff F, Mercken MH, Winter HL, Reynolds CH, Tounge BA, Luo C, Scott MK, Huang Y, Braeken M, Pieters SM, Berthelot DJ, Masure S, ... ... Parker MH, et al. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. Journal of Medicinal Chemistry. 50: 4261-4. PMID 17685503 DOI: 10.1021/jm0705408  1
2007 Du Y, Creighton CJ, Falcone BV, Parker MH, Gauthier DA, Reitz AB. Preparation of novel bicyclic piperazines by reduction of bicyclo[4.2.2]diketopiperazines: rearrangement involving 1,2-bond migration Tetrahedron Letters. 48: 6767-6770. DOI: 10.1016/j.tetlet.2007.07.080  1
2005 Parker MH, Maryanoff BE, Reitz AB. Synthesis of Carba-?-L-fructopyranose and Carbacyclic Analogues of Topiramate, an Anticonvulsant Agent. Cheminform. 36. DOI: 10.1002/CHIN.200508204  0.01
2002 Parker MH, Chen R, Conway KA, Lee DH, Luo C, Boyd RE, Nortey SO, Ross TM, Scott MK, Reitz AB. Synthesis of (-)-5,8-dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: an inhibitor of beta-amyloid(1-42) aggregation. Bioorganic & Medicinal Chemistry. 10: 3565-9. PMID 12213471 DOI: 10.1016/S0968-0896(02)00251-1  1
2001 Posner GH, Jeon HB, Parker MH, Krasavin M, Paik IH, Shapiro TA. Antimalarial simplified 3-aryltrioxanes: synthesis and preclinical efficacy/toxicity testing in rodents. Journal of Medicinal Chemistry. 44: 3054-8. PMID 11543673 DOI: 10.1021/jm0102396  1
1999 Posner GH, Ploypradith P, Parker MH, O'Dowd H, Woo SH, Northrop J, Krasavin M, Dolan P, Kensler TW, Xie S, Shapiro TA. Antimalarial, antiproliferative, and antitumor activities of artemisinin-derived, chemically robust, trioxane dimers. Journal of Medicinal Chemistry. 42: 4275-80. PMID 10543871 DOI: 10.1021/jm990363d  1
1999 Posner GH, Parker MH, Northrop J, Elias JS, Ploypradith P, Xie S, Shapiro TA. Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family. Journal of Medicinal Chemistry. 42: 300-4. PMID 9925735 DOI: 10.1021/jm980529v  1
1998 Woo SH, Parker MH, Ploypradith P, Northrop J, Posner GH. Direct conversion of pyranose anomeric OH→F→R in the artemisinin family of antimalarial trioxanes Tetrahedron Letters. 39: 1533-1536. DOI: 10.1016/S0040-4039(98)00132-4  1
1997 Jung ME, Parker MH. Synthesis of Several Naturally Occurring Polyhalogenated Monoterpenes of the Halomon Class(1). The Journal of Organic Chemistry. 62: 7094-7095. PMID 11671809  1
Show low-probability matches.